belapectin

Small molecule

GGalectin Therapeutics Inc.

belapectin is one of 11 small molecule programs targeting Esophageal Varices. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal VaricesActive, not recruiting

Esophageal VaricesPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Esophageal Varices

#DrugCompanyPhaseTrials

Coreg

Akero Therapeutics

Approved

6 2

Inderal

WWyeth-Lederle Vaccines

Approved

4 3

Sandostatin

Sun Pharma

Approved

2 4

Xifaxan

SSalix

Phase 3

1 5

Proton Pump Inhibitors

SSamsung Medical Center

Approved

1 6

Timolol Maleate

AAuson Pharmaceuticals Inc.

Phase 3

1 7

Fibrin Sealant

GGynecologic Oncology Group

Phase 3

1 8

Cyanoacrylate

KKaohsiung Veterans General Hospital.

Approved

1 9

Ledipasvir/sofosbuvir

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Preclinical

1 10

Anticoagulation Agents

IInari Medical

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatic Impairment1 trial

A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

Completed·GGalectin Therapeutics Inc.·Phase 1·NCT04332432·38 enrolled

Esophageal Varices1 trial

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis

Terminated·GGalectin Therapeutics Inc.·Preclinical·NCT04365868·357 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for belapectin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — belapectin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for belapectin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Galectin Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: GGalectin Therapeutics Inc.

belapectin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatic Impairment1 trial

Esophageal Varices1 trial

References

Drug Info

Quick Facts

Related News